Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

Health Pharma & Biotech Written by: Proactive 02:45 Fri 09 Oct 2026 --> Edited by: Jamie Ashcroft Proactive has a commercial relationship with Scancell Holdings PLC. This article was produced independently under Proactive's Editorial Standards Policy . Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Proactive Proactive leads the world in up-to-the-minute, multi-media news provision, events organisation, investor relations management and investor research Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Scancell Holdings PLC ( AIM:SCLP OTC:SCNLF ) View Price & Profile Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial Published: 02:45 09 Oct 2026 EDT Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) , the developer of cancer immunotherapies, is pressing ahead with plans to list on the Nasdaq stock exchange following an all-share merger with US biotech Neuphoria Therapeutics, announced in July. The combined company will trade under the ticker "SCLT" and retain the Scancell name, with shareholders voting on the deal at a general meeting on 20 October. The transaction comes with a substantial financing package that is expected to generate around $75 million on completion, drawn from a private placement, UK equity offerings and the first two tranches of a debt facility. Scancell raised £15.7 million through a UK placing and retail offer in late July and has since secured a $25 million loan facility from funds managed by BlackRock, the US asset manager. Funds managed by Redmile Group, a San Francisco-based healthcare investment firm, have agreed to convert their outstanding convertible loan notes into American Depositary Shares on completion of the merger. The Nasdaq push coincides with a critical period in Scancell's clinical programme. The company has received regulatory clearance from both the US Food and Drug Administration (FDA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to begin a phase III trial of its lead drug candidate, iSCIB1+, in advanced melanoma. The trial will enrol approximately 550 patients across sites in the US, EU, UK, Canada and Australia, with patients randomised to receive iSCIB1+ alongside the checkpoint inhibitor combination of ipilimumab and nivolumab, or a placebo alongside the same drug combination. Scancell expects to initiate the phase III study at some point this quarter. The company's annual results for the year to 30 April 2026 show an operating loss of £17.4 million, widening from £15.0 million the previous year, largely reflecting the absence of £4.7 million in licence revenue that Scancell received in 2025 from Danish antibody specialist Genmab. Research and development expenses fell to £12.0 million from £14.7 million, primarily due to lower manufacturing costs. Cash stood at £5.3 million at the period end, down from £16.9 million a year earlier, and Scancell acknowledged it does not currently have sufficient committed funding to meet its cash requirements for the next 12 months without the merger and private placement completing. Elsewhere in the pipeline, early data from the ModiFY trial of Modi-1 in head and neck cancer showed partial responses in three of the first seven patients, an overall response rate of 43% at 25 weeks. Further data from that trial are expected later in 2026. Continue reading